Addison CL - Search Results

1

VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.

Allen V, Coulombe J, Zhao H, Kreps LM, Cook DP, Pryce B, Clemons M, Vanderhyden BC, Gray DA, Addison CL. Allen V, et al. Among authors: addison cl. Br J Cancer. 2022 Jul;127(1):56-68. doi: 10.1038/s41416-022-01778-7. Epub 2022 Mar 22. Br J Cancer. 2022. PMID: 35318435 Free PMC article.

2

The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent.

Addison CL, Nör JE, Zhao H, Linn SA, Polverini PJ, Delaney CE. Addison CL, et al. BMC Cell Biol. 2005 Oct 31;6:38. doi: 10.1186/1471-2121-6-38. BMC Cell Biol. 2005. PMID: 16262896 Free PMC article.

3

Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells.

Delaney CE, Hopkins SP, Addison CL. Delaney CE, et al. Among authors: addison cl. Cancer Lett. 2007 Jul 18;252(2):195-207. doi: 10.1016/j.canlet.2006.12.027. Epub 2007 Feb 2. Cancer Lett. 2007. PMID: 17275999

4

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, Tsao MS, Shepherd FA, Bradbury PA. Addison CL, et al. J Clin Oncol. 2010 Dec 20;28(36):5247-56. doi: 10.1200/JCO.2010.31.0805. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079146

5

β1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner.

Schooley AM, Andrews NM, Zhao H, Addison CL. Schooley AM, et al. Among authors: addison cl. Cancer Lett. 2012 Mar 28;316(2):157-67. doi: 10.1016/j.canlet.2011.10.032. Epub 2011 Oct 30. Cancer Lett. 2012. PMID: 22099877

6

Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?

Clemons M, Russell K, Costa L, Addison CL. Clemons M, et al. Among authors: addison cl. Breast Cancer Res Treat. 2012 Jul;134(2):453-7. doi: 10.1007/s10549-012-2077-6. Epub 2012 May 5. Breast Cancer Res Treat. 2012. PMID: 22562125 Review.

7

Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

Kuchuk I, Clemons M, Addison C. Kuchuk I, et al. Curr Oncol. 2012 Oct;19(5):e303-4. doi: 10.3747/co.19.1009. Curr Oncol. 2012. PMID: 23144577 Free PMC article. No abstract available.

8

miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.

Honeywell DR, Cabrita MA, Zhao H, Dimitroulakos J, Addison CL. Honeywell DR, et al. Among authors: addison cl. PLoS One. 2013 Aug 7;8(8):e70515. doi: 10.1371/journal.pone.0070515. eCollection 2013. PLoS One. 2013. PMID: 23950948 Free PMC article.

9

The ZOOM trial: more boon than doom?

Hutton B, Addison CL, Clemons M. Hutton B, et al. Among authors: addison cl. Lancet Oncol. 2013 Sep;14(10):e387-8. doi: 10.1016/S1470-2045(13)70297-3. Lancet Oncol. 2013. PMID: 23993380 No abstract available.

10

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. Addison CL, et al. Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18. Breast Cancer Res Treat. 2014. PMID: 24638849 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page